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We investigated the anti-angiogenic effects of the water extract of HangAmDan (WEHAD), which is a crude extract of nine 
Korean medicinal substances of animal and plant origin. In human umbilical vein endothelial cells, WEHAD significantly in-
hibited bFGF-induced proliferation, adhesion, migration, and capillary tube formation. We used an antibody array to perform 
an analysis of signaling proteins, which showed up-regulated expression of various proteins including RAD51, RAD52, and 
p73, and down-regulated expression of pFAK. Blood vessel formation in a chick chorioallantoic membrane (CAM) treated 
with WEHAD was markedly reduced in length compared with a PBS-treated control group. These results suggest that inhibi-
tion of angiogenesis by WEHAD may be the mechanism of action for the anti-cancer effects of HAD. 
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Angiogenesis, which is the formation of new blood vessels 
from existing endothelium, is an essential process in various 
physiological and pathological situations including wound 
repair, organ regeneration, embryonic vascular system de-
velopment and tumorigenesis. Tumor growth and metastasis 
are highly dependent on angiogenesis [1,2]. Treatments for 
human cancer that inhibit angiogenesis are the subject of 
intensive clinical investigation and, therefore, better under-
standing of the fundamental mechanisms of angiogenesis is 
critical in developing and improving these novel therapeutic 
options. 
Angiogenesis is a complex process that involves the pro-
liferation and migration of endothelial cells. It is delicately 
controlled by a variety of inducers and inhibitors that re-
spectively cause the up- and down-regulation of angiogene-
sis [3,4]. It has been reported that most actively-studied 
basic fibroblast growth factors (bFGFs) and vascular endo-
thelial growth factors (VEGFs) work as angiogenic inducers 
for both in vivo and in vitro growth [5–7]. Many kinds of 
angiogenic inhibitors have already been discovered includ-
ing angiostatin, which decreases bFGF- and VEGF-media-      
ted activation of MAPK in endothelial cells leading to inhi-
bition of proliferation and induction of apoptosis [8]. Fur-
thermore, Soamsan, a traditional Korean medicinal extract of 
herbal materials, has been shown to have anti-angiogenic 
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effects and has been used to treat cardiovascular diseases [9]. 
Therapeutic inhibitors have been found using Proteo-
Chip-based library screening methods. For instance, the 
A5-1 peptide that is effective as an angiogenesis inhibitor 
against integrin α5β1 [10], and certain Korean medicinal 
plant extracts chosen under the same methodology have 
been verified to possess anti-angiogenic functions [11], 
have been identified using this methodology. 
HangAmDan (HAD) is composed of nine products from 
species of Korean medicinal plants and animals (Table 1), 
and has been used for the treatment of cancer patients in 
oriental medicine. We have investigated how the water ex-
tract of HAD (WEHAD) inhibits bFGF-induced angiogene-
sis using assays to measure the proliferation, migration, and 
adhesion of human umbilical vein endothelial cells (HU-
VECs) in vitro, and an ex vivo chorioallantoic membrane 
(CAM) angiogenesis assay. 
1  Materials and methods  
1.1  Preparation of water extract of HAD 
HAD was provided by the East-West Cancer Center of the 
Dunsan Oriental Medical Hospital of Daejeon University 
(Daejeon, Korea) (Table 1). The WEHAD was prepared by 
extracting HAD powder with 1 g of powder in 10 mL of 
distilled water at room temperature for 24 h. The extract 
was centrifuged at 1000×g for 30 min and then filtered and 
lyophilized. The extract powder was dissolved directly in 
distilled water. 
1.2  Cell culture  
Human umbilical vein endothelial cells (HUVECs) were 
provided from Innopharmascreen Inc. (Asan, Korea). Cells 
were cultured in a complete M199 medium (Invitrogen, CA, 
USA). The cells at passages 3–6 were used. HUVEC cul-
tures were kept maintained routinely at 37°C in a humidi-
fied atmosphere of 5% CO2, and used for assay at passages 
3–6. 
Table 1  Ingredients of HAD 
Scientific name Relative amount (mg) 
Coix lachryma Semen 259.0 
Panax notoginseng Radix 86.0 
Hippocampus kelloggi 26.0 
Cordyceps Militaris 26.0 
Santsigu Tuber 26.0 
Ginseng Radix 26.0 
Bovis Calculus 17.0 
Margarita 17.0 
Moschus 17.0 
Total amount (one capsule) 500.0 
1.3  In vitro HUVEC proliferation assay  
Assessment of cell proliferation was performed according to 
the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-te- 
trazolium bromide) assay protocol. HUVECs (1×104 cells/ 
well) were added to 96-well tissue culture plates coated 
with gelatin and allowed to adhere overnight. The cells were 
treated with extract in the presence or absence of bFGF and 
incubated for 72 h. Then, 50 μL of a 1 mg mL−1 MTT solu-
tion was added to each well, and the cells were incubated 
for 2 h at 37°C. After the supernatants were discarded, re-
sidual formazan crystals were dissolved in 100 μL of 
DMSO. Absorbance was measured at 595 nm on an ELISA 
plate reader (Emax, Molecular Devices, USA). GRGDSP 
(PEPTRON, Daejeon, Korea), a synthetic peptide, is the 
peptide including Arg-Gly-Asp (RGD) in which the motif 
acts as various integrin-recognition motifs. It is extensively 
used as inhibitors of integrin-ligand interactions as well as 
in the study on cell adhesion, migration, growth and differ-
entiation [12]. On the other hand, GRGESP (PEPTRON, 
Daejeon, Korea) is the peptide which loses the function of 
RGD by changing Asp of motif of RGD into Glu. It is also 
used as a control group along with RGD. The presented data 
were measured in triplicate. 
1.4  In vitro HUVEC adhesion assay 
An adhesion substrate was prepared by adding 100 μL of 
vitronectin (10 μg mL−1; Sigma, St. Louis, USA) diluted in 
phosphate-buffered saline (PBS; pH 7.3) to 96-well ELISA 
plates (Nunc) overnight at 4°C. Each well was then washed 
twice with PBS to remove unbound vitronectin and blocked 
for 30 min at 37°C with 0.1% bovine serum albumin (BSA) 
in PBS. After blocking, the wells were washed three times 
with PBS. 
HUVECs (5×105 cells mL−1) were added to each well of 
a 96-well plate coated with fibronectin. HUVEC suspension 
(100 μL) including either fresh media (negative control) or 
WEHAD (30–1000 μg mL−1) and bFGF (5 ng mL−1) was 
added to three wells and incubated for 90 min at 37°C. Af-
ter incubation, unbound cells were removed by rinsing each 
well twice with PBS and incubated for 1 h at 37°C with 
100 μL 1% Coomassie blue solution (v/v) that diluted with 
MeOH. The optical density (A) at 595 nm of each well was 
measured using a spectrophotometer (Emax, Molecular De-
vices, USA). The presented data were measured in tripli-
cate. 
1.5  In vitro HUVEC migration assay 
A migration assay was performed as previously [13,14]. 
HUVECs were placed in a modified Boyden chamber 
(48-well chemotaxis chamber AP48; Neuro Probe, Gaith-     
ersburg, MD, USA). Polycarbonate membranes (8 μm pore, 
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25 mm×80 mm in size, polyvinylpyrrolidine-free; Neuro 
Probe) were coated with gelatin and incubated overnight at 
37°C. Basic FGF (5 ng mL−1) in M199 was added to the 
lower chamber, and cell suspension containing 1×104 cells 
per 50 μL media and supplemented with the indicated 
concentration of medicinal extracts was added to the upper 
chamber of each well. The chamber was incubated for 8 h at 
37°C with 5% CO2 to allow cells to migrate through the 
gelatin-coated polycarbonate membrane. Non-migrating 
cells on the upper surface of the membrane were removed 
with a wiper tool (Neuro Probe), and the membrane was 
then stained with Diff-Quik (VWR Scientific Products, 
Bridgeport, NJ, USA). The total number per well of mi-
grating cells with nuclei was determined as described. The 
evaluated data showed the relative cell migration, which is a 
percentage compared with the mean cell number for each 
stained field. The presented data were measured in tripli-
cate. 
1.6  In vitro capillary tube formation 
Capillary tube formation of HUVECs was performed as 
described with some modification [15]. Twenty four-well 
culture plates were coated with 250 μL of Matrigel and al-
lowed to solidify at 37°C for 30 min. HUVECs (2×105 cells) 
were added to each of three wells in 100 μL of media con-
taining WEHAD and bFGF of 5 ng mL−1 (or fresh media as 
a negative control). After 18 h of incubation, the capillary 
tubes were fixed, stained with a Diff-Quick solution (Bec-
ton Dickinson, San Jose, CA, USA) and observed under a 
phase-contrast microscope. 
1.7  Ex vivo bFGF-induced CAM angiogenesis 
An ex vivo CAM assay was performed as previously de-
scribed [16,17]. Fertilized eggs were incubated at 37°C in 
humidified air. Ovalbumin (4–5 mL) was extracted from the 
bottom of the eggs using a syringe on day 3, and windows 
were made within the tops of the eggs. The windows were 
sealed with transparent tape, and the eggs were further in-
cubated until day 9. Thermonox (Nunc, Naperville, IL) 
containing bFGF (200 ng) or bFGF plus extract was im-
planted onto the CAM of an individual embryo. After a 48 h 
incubation period, intralipose (a white fat emulsion solu-
tion) was injected into the CAM for clear visualization of 
blood vessel formation, and each CAM was observed under 
a microscope and photographed. 
1.8  Protein expression profiling in WEHAD-treated 
HUVEC 
1.8.1  Preparation of cell lysates  
When HUVECs reached confluence, they were serum-     
starved by incubation in M199 containing 1% FBS for 8 h. 
The cells were treated with or without WEHAD in the 
presence of growth factor. After 24 h incubation, the cells 
were washed twice with PBS and harvested in 5 mmol L−1 
EDTA-PBS. The harvested cells were then maintained on 
ice for 10 min and centrifuged for 5 min at 1300 r min−1. 
The pellets were washed with PBS and re-centrifuged. 
1.8.2  Protein extraction and labeling 
HUVECs were extracted with Lysis-M™ (Roche, Germany) 
mammalian cell extraction buffer. Each protein extract (100 
μg, 1 mg mL−1) was labeled with both Cy3 and Cy5 (GE 
Healthcare, UK) as per the manufacturer’s instructions. Free 
dyes were removed with SigmaSpin columns (S5059, 
Sigma, USA) and purified samples were stored at 4°C until 
use. 
1.8.3  Preparation of antibody microarrays 
Forty-eight distinct antibodies against proteins involved in 
cell proliferation (Hypromatrix, Worcester, MA, USA) 
were spotted onto ProteoChip arrays in duplicate. The de-
tailed procedure of array analysis has been previously de-
scribed [18]. 
1.8.4  Hybridization  
The fluorescence-labeled cell lysates were applied onto the 
antibody array and incubated for 1 h at 37°C in the dark. 
The slides were washed three times with PBST, N2-dried 
and analyzed using a fluorescence microarray scanner. 
1.8.5  Detection and data analysis  
The antibody array slides were scanned using a GenePix 
4100A microarray scanner (Axon Instruments, Union City, 
CA, USA) with 532 and 635 nm lasers. Image analysis was 
performed for each spot using the manufacturer’s software 
package (GenePix 6.0, Axon Instruments). The INR (inter-
nally normalized ratio) of all spots were calculated as pre-
viously described [19]. 
1.8.6  Western-blot analysis 
The cell pellets were lysed using Complete Lysis M 
(Roche). Protease and phosphatase inhibitor cocktails (both 
from Roche) were added. Protein extracts (50 μg) were 
separated on a 12% Bis-Tris Nupage gel (Invitrogen) and 
transferred onto a PVDF membrane. The membrane was 
blocked with 5% non-fat milk, or BSA in PBS (pH 7.4) 
containing 0.5% Tween-20. It was then incubated with rabbit 
anti-FAK (1:1000 dilution), rabbit anti-Rad51 (1:1000 dilu-
tion), rabbit anti-p73 (1:1000 dilution), or rabbit anti-GAPDH 
(1:500 dilution) for 16 h at 4°C. The membrane was sub-
sequently incubated with horseradish peroxidase-conjugated 
anti-rabbit secondary antibodies for 60 min at room tem-
perature. Protein bands were visualized on a medical X-ray 
film (Agfa) using an enhanced chemiluminescence (ECL™) 
kit (Invitrogen). 
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2  Results and discussion 
2.1  Biological characterization of WEHAD effects on 
bFGF-induced HUVECs  
To investigate the biological activities of WEHAD, we per-
formed proliferation, migration, and adhesion assays using 
HUVECs. As an antagonistic extract, WEHAD markedly 
inhibited the proliferation of HUVECs compared with the 
PBS-treated control group (Figure 1A). A half-maximal 
inhibition of proliferation on the endothelial cells by 
WEHAD was observed at a concentration of 253 μg mL−1. 
To confirm the anti-angiogenic functions of WEHAD, an 
in vitro HUVEC adhesion assay and a migration assay were 
employed. WEHAD suppressed bFGF-induced cell attach-
ment in a dose-dependent manner (Figure 1B). The anti-     
adhesive efficacy of WEHAD was higher than that of RGD. 
WEHAD also prevented bFGF-induced cell migration in a 
dose-dependent manner compared with the PBS control 
group (Figure 1C). To further assess the inhibitory effects of 
the antagonistic extracts on HUVEC proliferation, we car-
ried out an in vitro capillary tube formation assay, and ex 
vivo CAM angiogenesis. Cells plated on Matrigel were 
treated for 16 h with WEHAD in the presence of bFGF and 
tube formation was observed using phase-contrast micros-
copy. WEHAD significantly suppressed tube formation at a 
concentration of 10 μg mL−1 (Figure 2A). The area of CAM 
below the disks without any treatment showed a normal 
density and branching pattern of the blood vessels, indicat-
ing that disk weight did not affect their growth. By contrast, 
the vascular branches of CAM treated with WEHAD (10 μg/ 
egg) for 48 h were perturbed (Figure 2B). These findings 
are consistent with data obtained from HUVEC prolifera-





Figure 1  Inhibitory effect of WEHAD on HUVECs. A, Cell proliferation. HUVECs were incubated with different concentrations (7–1000 μg mL−1) of 
WEHAD for 72 h in the presence of bFGF (5 ng mL−1). After incubation, unbound cells were removed with PBS and incubated for 2 h with 100 μL of an 
MTT solution. Absorbance was measured at 595 nm using an ELISA reader. Control cells were incubated in the absence of bFGF and WEHAD, whereas 
bFGF-control cells were incubated in the presence of bFGF alone (dotted line). B, Attachment. HUVECs were incubated with different concentrations 
(30–1000 μg mL−1) of WEHAD for 90 min in the presence of bFGF (5 ng mL−1) on fibronectin-coated 96-well ELISA plates. After incubation, unbound 
cells were removed with PBS, and attached cells were fixed with methanol and stained with crystal violet. C, Migration. Dose-dependent inhibition of 
bFGF-induced HUVEC migration by WEHAD was examined. The total number of cells per field (Y-axis) was measured using an Image Gauge V2.54 pro-
gram. Control cells were incubated in the absence of bFGF and WEHAD, whereas bFGF-control cells were incubated in the presence of bFGF alone (dotted  
line). GRGDSP and GRGESP were used as a positive and a negative control, respectively. 
252 Bang J Y, et al.   Sci China Life Sci   March (2011) Vol.54 No.3 
 
 
Figure 2  Inhibitory effects of WEHAD on capillary tube formation and 
bFGF-induced CAM angiogenesis. A, HUVECs were seeded on Ma-
trigel-coated 24-well plates in serum-free media containing GRGDSP or 
WEHAD in the presence of bFGF (5 ng mL−1) or PBS alone. After 18 h, 
the capillary tubular network was stained with a Diff-Quick solution (Bec-
ton Dickinson, San Jose, CA, USA) and observed under a phase-contrast 
microscope. B, Thermonox discs containing bFGF alone, RGD (10 μg/egg), 
and WEHAD (10 μg/egg) in the presence of bFGF (200 ng/egg) were 
tested on each of 10 CAMs on nine-day-old chick embryos. After a 48 h 
incubation period, the CAMs were observed. A negative control was incu- 
bated in the absence of bFGF. GRGDSP was used as a positive control. 
assays. Collectively, these results suggest that WEHAD 
could be useful for the development of a potent angiogene-
sis inhibitor. 
2.2  Expression profiling of cell cycle proteins in 
WEHAD-treated HUVECs using antibody microarray 
The goal of this study was to analyze the expression pattern 
of endogenous signaling proteins in HUVECs treated with 
WEHAD. To investigate the protein expression profile in 
WEHAD-treated HUVECs, an antibody microarray con-
structed on ProteoChip was used. To carry out the antibody 
microarray analysis, WEHAD-treated HUVECs were la-
beled with Cy3 and Cy5. 
Antibody microarray analysis of WEHAD-treated HU-
VECs labeled with Cy5 compared with the Cy3-labeled 
untreated HUVECs revealed up- or down-regulation of dif-
ferent proteins (Figure 3A and B). A further attempt was 
made to validate the antibody microarray data by im-
munoblot analysis. Selected up-regulated proteins such as 
RAD51, Cyclin B1, and p73 showed increased expression, 
whereas down-regulated proteins such as FAK showed a 
decrease in protein amount in Western blotting analyses 
(Figure 3C). 
Focal adhesion kinase (FAK) is a widely expressed cyto-
plasmic protein tyrosine kinase involved in integrin-medi-     
ated signal transduction. It plays an important role in the 
control of several biological processes including cell 
spreading, migration, and survival [20]. Our antibody array 
data indicate that the inhibitory effect of WEHAD on the 
proliferation of HUVECs may be partly due to the de-
creased expression of FAK involved in integrin-mediated 
cell survival. p73, a member of the p53 family, is involved 
in cell cycle regulation, and induction of apoptosis. The 
p73-induced apoptosis is mediated by endoplasmic 
reticulum stress and induction of p53 up-regulated 
modulator of apoptosis (PUMA) [21,22]. Our finding 
suggests that the inhibition of HUVEC proliferation by 
WEHAD may be mediated by induction of apoptosis in the 
cells via increased p73 expression. It was reported that en-
hancement of p53 ubiquitination by the FAK FERM domain 
promotes cell proliferation and cell survival [23]. Based on 
our antibody array data, WEHAD treatment of HUVECs 
caused down-regulation of FAK as well as up-regulation of 
p73, resulting in suppression of cell proliferation. Addition-
ally, the DNA repair protein, RAD51, was regulated by 
WEHAD in HUVECs. Collectively, these data suggest that 
WEHAD significantly inhibits bFGF-induced angiogenesis 
through the regulation of expression of certain proteins in-
volved in cell growth. 
In this study, we observed anti-angiogenic effects of 
WEHAD in HUVECs through different angiogenesis assays 
induced by bFGF. WEHAD had dose-dependent inhibitory 
effects on proliferation, migration and adhesion (Figure 1). 
We also verified this inhibitory effect through an ex vivo 
CAM assay (Figure 2B). Thus, WEHAD may have a poten-
tial therapeutic utility in the treatment of cancers involving 
neovascularization. However, as we already described, 
WEHAD is a natural product made up of nine types of 
plants and animals, i.e., it contains many types of com-
pounds. Thus, further attempts will be made to examine the 
molecular mechanism correlated with cellular signaling 
pathways, and to identify the active compounds that appear 
to create the anti-angiogenic effects of WEHAD. 
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Figure 3  Analysis of differential expression of cell cycle proteins in HUVECs treated with WEHAD using the antibody microarray. A, Graded virtual 
image of Cy5:Cy3 ratios at spots within arrays of protein extracts from WEHAD-treated HUVECs and validation of antibody microarray data by im-
munoblot analysis. B, Map of the antibody chip. Up- and down-regulated proteins are shown by red and blue, respectively. C, Graphical representation of 
Cy5:Cy3 ratios on the antibody arrays. The bar chart shows the mean fluorescent intensity of three spots plotted over three independent experiments. Pro- 
teins having a normal median ratio in the range of 1.0 were considered as unchanged expression. 
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